DelveInsight’s “Medullary Thyroid Cancer Pipeline Insight 2023” report provides comprehensive global Medullary Thyroid Cancer coverage of available, marketed, and Medullary Thyroid Cancer Pipeline therapies in various stages of Medullary Thyroid Cancer clinical trials development, major pharmaceutical Medullary Thyroid Cancer Companies are working to advance the Medullary Thyroid Cancer pipeline space and future growth potential of the Medullary Thyroid Cancer pipeline domain.
For Medullary Thyroid Cancer emerging drugs, the Medullary Thyroid Cancer pipeline analysis report provides a 360° view of the Medullary Thyroid Cancer pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Medullary Thyroid Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Medullary Thyroid Cancer Pipeline Insight Report
- Over 15+ Medullary Thyroid Cancer companies are evaluating 15+ Medullary Thyroid Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Medullary Thyroid Cancer market would significantly increase market revenue.
- The Medullary Thyroid Cancer Companies includes Bristol-Myers Squibb, Takeda, NantCell, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer, Novartis, Hutchison Medipharma Limited, Turning Point Therapeutics Inc., and others.
- Promising Medullary Thyroid Cancer Pipeline Therapies includes Selpercatinib, Cabozantinib (XL184) 140 mg, Vandetanib 300 mg, Anlotinib, Caprelsa, XL184, omeprazole, ranitidine, ZD6474 (vandetanib), and others.
- The Medullary Thyroid Cancer companies and academics are working to assess challenges and seek opportunities that could influence Medullary Thyroid Cancer R&D. The Medullary Thyroid Cancer pipeline therapies under development are focused on novel approaches to treat/improve Medullary Thyroid Cancer.
Request a sample and discover the recent breakthroughs happening in Medullary Thyroid Cancer Pipeline Landscape @ Medullary Thyroid Cancer Pipeline Outlook Report
Medullary Thyroid Cancer Overview
Medullary thyroid cancer, or MTC, is a cancer that forms in the thyroid. The thyroid is a gland located in the front of your neck, just below the Adam’s apple. It is responsible for sending out hormones to the rest of your body. The inside of the thyroid is called the medulla. The medulla contains special cells called parafollicular C cells that produce and release hormones. MTC happens when the C cells become cancerous and grow out of control. MTC may also be called medullary thyroid carcinoma. Thyroid cancer is fairly common. There are four different types of thyroid cancers and MTC is the rarest type making up 3% to 4% of all thyroid cancers. About 1,000 people are diagnosed with MTC each year in the U.S. MTC can start as a lump in the throat. The tumor growing in the thyroid can make your voice hoarse by blocking your vocal chords or it can make it hard to breathe by blocking your windpipe.
Medullary Thyroid Cancer Emerging Drugs Profile
- Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2. It releases PD-1 pathway-mediated inhibition of inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth. Currently, it is in Phase II stage of clinical trial evaluation to treat Medullary Thyroid Cancer.
- Regorafenib: Bayer
Regorafenib is a small-molecule multikinase inhibitor that specifically inhibits epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor-ß (PDGFRB), fibroblast growth factor receptor 1 (FGFR1), and the mutant oncogenic kinases KIT, RET, and B-RAF. Several clinical trials have studied the association between regorafenib response and angiogenesis biomarkers in blood. Higher concentrations of VEGF family ligands, such as PIGF, and lower levels of TIMP2, soluble VEGF receptor 2, and TIE-1 have been associated with the response to regorafenib. A biomarker analysis from the CORRECT clinical trial for regorafenib efficacy in patients with mCRC showed that in both KRAS wild-type and mutant statuses, low levels of circulating free DNA and high levels of TIE-1 in plasma were associated with a clinical benefit. Furthermore, the single-nucleotide polymorphism (SNP) rs2010963 in the VEGF-A gene correlated with an improved PFS and OS in this trial. Thus, genotyping analysis may be useful for the selection of patients who could potentially benefit from regorafenib treatment. Currently, it is in Phase II stage of clinical trial evaluation to treat Medullary Thyroid Cancer.
Find out more about the Medullary Thyroid Cancer Diagnosis and Treatment of patients @ Medullary Thyroid Cancer Ongoing Clinical Trials Analysis
Medullary Thyroid Cancer Pipeline Therapies and Companies
- Bristol-Myers Squibb: Selpercatinib
- Takeda: Cabozantinib (XL184) 140 mg
- NantCell Inc: Vandetanib 300 mg
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd: Anlotinib
- CSPC ZhongQi Pharmaceutical Technology Co Ltd: Caprelsa
- Bayer: XL184
- Novartis: Omeprazole
- Hutchison Medipharma Limited: Ranitidine
- Turning Point Therapeutics Inc: ZD6474 (vandetanib)
Medullary Thyroid Cancer Pipeline Therapeutics Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Discover more about the list of Medullary Thyroid Cancer FDA-approved drugs for Medullary Thyroid Cancer @ Medullary Thyroid Cancer Treatment Landscape
Scope of the Medullary Thyroid Cancer Pipeline Report
- Coverage- Global
- Medullary Thyroid Cancer Companies- Bristol-Myers Squibb (NYSE: BMY), Takeda (NYSE: TAK), NantCell, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer (NYSE: BAY), Novartis (NYSE: NVS), Hutchison Medipharma Limited, Turning Point Therapeutics Inc.(NYSE: TPTX), and others.
- Medullary Thyroid Cancer Pipeline Therapies- Selpercatinib, Cabozantinib (XL184) 140 mg, Vandetanib 300 mg, Anlotinib, Caprelsa, XL184, omeprazole, ranitidine, ZD6474 (vandetanib), and others
- Medullary Thyroid Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for Medullary Thyroid Cancer Emerging Therapies and Ongoing Clinical Trials; visit @ Medullary Thyroid Cancer Emerging Therapies and Companies
Table of Content
- Introduction
- Executive Summary
- Medullary Thyroid Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Medullary Thyroid Cancer – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Nivolumab: Bristol-Myers Squibb
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Medullary Thyroid Cancer Key Companies
- Medullary Thyroid Cancer Key Products
- Medullary Thyroid Cancer- Unmet Needs
- Medullary Thyroid Cancer- Market Drivers and Barriers
- Medullary Thyroid Cancer- Future Perspectives and Conclusion
- Medullary Thyroid Cancer Analyst Views
- Medullary Thyroid Cancer Key Companies
- Appendix
For further information on the Medullary Thyroid Cancer Pipeline therapeutics, reach out @ Medullary Thyroid Cancer Market Drivers and Barriers
Latest Pharmaceuticals Market Research Reports
Technical due diligence | Monoclonal Gammopathy of undetermined significance market | Stem cell market | Varicose vein treatment devices market | Oncolytic virus cancer therapy pipeline | Scabies market | Technical due diligence firms | Schistosomiasis market | Lactose intolerance market | Axillary hyperhidrosis market | Cold agglutinin disease market | Complement 3 Glomerulopathy market | Immune checkpoints activator companies | Moderate psoriasis market | Nocturia market | Parainfluenza virus infection market | Polymyalgia Rheumatica market | Presbyopia market | Secondary progressive multiple sclerosis SPMS market | Shigella infections market | Smallpox market | Spinocerebellar ataxia market |Thymidine kinase 2 deficiency market | Coronary Microvascular dysfunction CMD market | Drug-resistant epilepsy market | Pertussis market | Hypoxic ischemic encephalopathy market | Trichotillomania market | Myopia progression market | Temporomandibular disorders market | Immune thrombocytopenia market | Spondylolisthesis market | Supraventricular tachycardia market | Tay-sachs disease market | Varicella zoster HHV 3 infections market | X-linked retinitis Pigmentosa market | Progressive Supranuclear palsy market report | Sly syndrome Market | Erosive hand osteoarthritis market | Coronary stents pipeline
Latest Healthcare Blogs
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com